CTS-21166

CTS-21166 is a blood-brain barrier-permeable and orally active BACE1 inhibitor. CTS-21166 reduces brain Aβ levels. CTS-21166 can be used in the research of Alzheimer's disease[1][2].

Product Specifications

CAS Number

[1226777-95-2]

UNSPSC

12352005

Target

Amyloid-β; Beta-secretase

Related Pathways

Neuronal Signaling

Field of Research

Neurological Disease

Smiles

O=C(C1=CC(N(C)S(=O)(C)=O)=CC(C(N[C@@H](C)[C@@H](C)C[C@@H](C)C(N[C@H](C(NC(C)C)=O)C(C)C)=O)=O)=C1)N[C@@H](C2=CC=CC=C2)C

Molecular Formula

C34H51N5O6S

Molecular Weight

657.86

References & Citations

[1]Yan R. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13. |[2]Menting KW, et al. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Front Aging Neurosci. 2014 Jul 21;6:165.